Cosmo should see a sharp increase in revenues boosted by the recovery of its endoscopy business, which was severely impacted by the COVID-19 pandemic, and the US launch of Winlevi in acne. Revenues from game changer GI Genius could be transformational. Cosmo has returned to sustainable profits.
Key catalysts include:
1. Start phase III trial Aemcolo in IBS-D (2022)
2. Start confirmatory Lumeblue phase III trial for US approval (2022)
3. Start phase III trial Breezula in male alopecia (H2 2022)